Author
Listed:
- Yuxi Chen
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University
Sun Yat-sen University)
- Jiaqi Liu
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University)
- Shengyao Zhi
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University)
- Qi Zheng
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University)
- Wenbin Ma
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University)
- Junjiu Huang
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University
Sun Yat-sen University)
- Yizhi Liu
(Sun Yat-sen University)
- Dan Liu
(Baylor College of Medicine, One Baylor Plaza)
- Puping Liang
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University)
- Zhou Songyang
(Sun Yat-sen University; MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University
Sun Yat-sen University
Baylor College of Medicine, One Baylor Plaza
Guangzhou Regenerative Medicine and Health-Guangdong Laboratory (GRMH-GDL))
Abstract
Class 2 CRISPR–Cas proteins have been widely developed as genome editing and transcriptional regulating tools. Class 1 type I CRISPR–Cas constitutes ~60% of all the CRISPR–Cas systems. However, only type I–B and I–E systems have been used to control mammalian gene expression and for genome editing. Here we demonstrate the feasibility of using type I–F system to regulate human gene expression. By fusing transcription activation domain to Pseudomonas aeruginosa type I–F Cas proteins, we activate gene transcription in human cells. In most cases, type I–F system is more efficient than other CRISPR-based systems. Transcription activation is enhanced by elongating the crRNA. In addition, we achieve multiplexed gene activation with a crRNA array. Furthermore, type I–F system activates target genes specifically without off-target transcription activation. These data demonstrate the robustness and programmability of type I–F CRISPR–Cas in human cells.
Suggested Citation
Yuxi Chen & Jiaqi Liu & Shengyao Zhi & Qi Zheng & Wenbin Ma & Junjiu Huang & Yizhi Liu & Dan Liu & Puping Liang & Zhou Songyang, 2020.
"Repurposing type I–F CRISPR–Cas system as a transcriptional activation tool in human cells,"
Nature Communications, Nature, vol. 11(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16880-8
DOI: 10.1038/s41467-020-16880-8
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Rui Chen & Xinyao Shi & Xiangrui Yao & Tong Gao & Guangyu Huang & Duo Ning & Zemin Cao & Youxin Xu & Weizheng Liang & Simon Zhongyuan Tian & Qionghua Zhu & Liang Fang & Meizhen Zheng & Yuhui Hu & Huan, 2024.
"Specific multivalent molecules boost CRISPR-mediated transcriptional activation,"
Nature Communications, Nature, vol. 15(1), pages 1-13, December.
- Meiling Lu & Chenlin Yu & Yuwen Zhang & Wenjun Ju & Zhi Ye & Chenyang Hua & Jinze Mao & Chunyi Hu & Zhenhuang Yang & Yibei Xiao, 2024.
"Structure and genome editing of type I-B CRISPR-Cas,"
Nature Communications, Nature, vol. 15(1), pages 1-12, December.
- Jing Guo & Luyao Gong & Haiying Yu & Ming Li & Qiaohui An & Zhenquan Liu & Shuru Fan & Changjialian Yang & Dahe Zhao & Jing Han & Hua Xiang, 2024.
"Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells,"
Nature Communications, Nature, vol. 15(1), pages 1-16, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16880-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.